ALK and non-small cell lung carcinoma: One phase III clinical trial found that adding pembrolizumab to standard chemotherapy consisting of pemetrexed and platinum‐based drugs can prolong OS and PFS in patients with metastatic nonsquamous NSCLC who did not receive prior therapy and were negative for EGFR and ALK mutations [14].